-+ 0.00%
-+ 0.00%
-+ 0.00%
Haizheng Pharmaceutical (600267.SH): Bedaquiline fumarate tablets obtained drug registration certificate
Share
Listen to the news

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for bedaquiline fumarate tablets approved and issued by the State Drug Administration. Bedaquiline fumarate tablets are a Class B drug in the medical insurance list. It is a diarylquinoline antimycobacterial drug. As part of combination treatment, it is suitable for the treatment of at least adults and adolescents (12 to <18 years old and body weight ≥30 kg) caused by Mycobacterium tuberculosis resistant to rifampicin and isoniazid.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending